Stapley Marc 4

What Happened
Marc Stapley, CEO of Veracyte, reported open‑market sales of a total 45,523 shares on March 4, 2026. The filing lists two disposals: 19,244 shares at a weighted average price of $35.56 for $684,226, and 26,279 shares at a weighted average price of $36.28 for $953,368 — combined proceeds of roughly $1.64 million. These were sales (not purchases), which are often routine when executed under prearranged plans.

Key Details

• Transaction date: 2026-03-04; Form 4 filed: 2026-03-06 (appears timely — within the two‑business‑day reporting window).
• Reported disposals: 19,244 shares @ $35.56 (= $684,226) and 26,279 shares @ $36.28 (= $953,368); total 45,523 shares, ≈ $1,637,594.
• Footnote F1: Transactions executed under a Rule 10b5‑1 trading plan adopted by Stapley on November 24, 2025.
• Footnotes F2/F3: Prices reported are weighted averages; underlying sale prices ranged approximately $35.00–$36.00 (for the first lot) and $36.01–$36.51 (for the second). A per‑price breakout is available to the SEC, issuer, or shareholders on request.
• Shares owned after the transaction: not specified in the provided filing summary.

Context
Sales under a 10b5‑1 plan are prearranged and scheduled in advance, which is common for insiders managing diversification or liquidity needs; they do not necessarily reflect the insider’s view of the company. This report documents straight sales (transaction code S), not option exercises, gifts, or grants.